Figure 1 | Scientific Reports

Figure 1

From: CG200745, an HDAC inhibitor, induces anti-tumour effects in cholangiocarcinoma cell lines via miRNAs targeting the Hippo pathway

Figure 1

Anti-proliferative activities of HDAC inhibitors against SNU-1196, SNU-1196/GR, and SNU-308 cells. Cell viability was assessed with the MTT assay. (a) IC50 values of CG200745 were 0.6, 0.9, and 1.8 μM, respectively; (b) IC50 values of entinostat were 16.4, 48.8, and 6.7 μM, respectively; and (c) IC50 values of vorinostat were 1.2, 2.6, and 3.9 μM, respectively. In SNU-1196 and SNU-1196/GR cells, (d) CG200745 (IC50) induced the expression of apoptosis-related proteins p21 and BAX, as determined by western blotting; (e) CG200745 (IC50) inhibited the expression of multidrug resistance genes, as determined by PCR; and (f) CG200745 (IC50) altered the expression level of HDAC isozyme, as determined by western blotting.

Back to article page